December 9, 2016 09:40 AM EST

Synergy outlines upbeat PhIII data; Bluebird and Blueprint raising $375M

Shehla Shakoor

Managing Director

Synergy Pharmaceuticals $SGYP is following up on the late-stage success of its lead drug plecanatide for chronic idiopathic constipation with a new batch of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Synergy outlines upbeat PhIII data; Bluebird and Blueprint raising $375M

Shehla Shakoor

Managing Director

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Netherlands pours $1.5B into biotech in pursuit of global leadership ambitions

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Syn­er­gy out­lines up­beat PhI­II da­ta; Blue­bird and Blue­print rais­ing $375M

Managing Director

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Synergy outlines upbeat PhIII data; Bluebird and Blueprint raising $375M